



Strategic Approaches to Vaccine Design Against Negative Strand Virus Diseases

Guest Editor:

Prof. Dr. S. Louise Cosby

1. School of Medicine, Dentistry
and Biomedical Sciences,
Queen's University Belfast,
Belfast BT9 7BL, UK

2. Virology, Veterinary Sciences
Division, Agri-Food and
Biosciences Institute, Belfast BT4
3SD, UK

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

Vaccines are designed to induce an immune response which will mimic part or all of the response to the actual pathogen. A requirement is for immunological memory to be established resulting in rapid recall when the wild type infection is encountered. For viral vaccines this memory response needs to ideally induce both humoral and cell mediated responses and be fully protective against the disease developing. Ideally sterilising immunity should be achieved to prevent virus transmission to other individuals. Many approaches have been taken to design virus vaccines against negative strand viruses (NSV) to try and achieve this aim with some more successful than others. These include more conventional attenuated and inactivated vaccines as well as subunit, vectored or nucleic acid vaccines. In the veterinary world, vaccines differentiating infected from vaccinated animals (DIVA) vaccines are often required along with associated discriminating immunological assays.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com